We have updated our Terms of Use.
Please read our new Privacy Statement before continuing.

Righting the wrong

15 December 2010 By Pierre Briancon

The Swiss drugmaker has upped its offer to Alcon’s minority shareholders to $168 a share the same it is paying Nestle for its 77 pct stake. Alcon’s independent directors have won their spirited fight. Now Novartis can extract the synergies it needs from the $52 bln deal.

This content is for Subscribers only

 

Email a friend

Please complete the form below.

Required fields *

*
*
*

(Separate multiple email addresses with commas)